Brief: Klaria Pharma Presents New Strategy

Klaria Pharma Holding AB (publ)

30/01/2020 07:36

Jan 30 (Reuters) - Klaria Pharma Holding AB (publ)
 KLAR.ST :
    * KLARIA PHARMA PRESENTS NEW STRATEGY, UPCOMING MILESTONES
AND NEW
WEBSITE
    * KLARIA IS NOW AIMING TO ACHIEVE SEVERAL IMPORTANT
MILESTONES
    * MILESTONE: COMPLETION OF BIOEQUIVALENCE STUDIES AND
PREPARATION
OF AN APPLICATION FOR MARKET APPROVAL FOR SUMATRIPTAN AGAINST
ACUTE MIGRAINE
    * MILESTONE: REACH CLINICAL PHASE WITH ADRENALINE TREATMENT
AGAINST ACUTE ALLERGIC REACTION (WITH PARTNER MUNDIPHARMA/PURDUE
PHARMA CANADA)
    * MILESTONE: REACHING CLINICAL PHASE WITH NALOXONE AGAINST
OPIOID
OVERDOSE
    * MILESTONE: REACHING CLINICAL PHASE WITH KETAMINE AGAINST
ACUTE
PAIN AND DEPRESSION.
    * KLARIA WILL FOCUS ALL RESEARCH AND DEVELOPMENT EXCLUSIVELY
ON
PROGRAMS WHERE KLARIA'S FILMS HAVE POTENTIAL TO REPLACE
INJECTIONS OR NASAL SPRAYS, AND WHERE FORMULATIONS CONSTITUTE A
MAJOR PROBLEM FOR PATIENTS, CAREGIVERS OR PAYERS

Source text for Eikon:  ID:nWkr4k7TlT 
Further company coverage:  KLAR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))